Cell And Gene Therapy Manufacturing

  1. Mitigating Risk In Process Automation 8/18/2023

    Two Chief Technical Officer's for therapeutic organizations cover the various ways in which automation helps to reduce risk and why closing systems and reducing the number of manual manipulations is so critical.

  2. Thermo Fisher Scientific Customer Testimonial - Libbs 9/20/2018

    An overview of Libbs product portfolio and how they benefit from Thermo Fisher Scientific services.

  3. Technology Needs For Automated Manufacturing 8/18/2023

    Investigate the importance of technology as it relates to automation and standardization within cell therapy manufacturing. The panelists in this discussion cover solutions and services needed for process automation in CGT.

  4. Accelerating Process Scale-Up From Benchtop To Commercialization- From Controller To Software 11/4/2025

    Discover strategies for optimizing process control, refining media selection, and ensuring safety through rigorous contaminant detection to mitigate development risks.

  5. CaptureSelect™ Technology - Powerful Affinity For More Streamlined Purification 11/4/2025

    Replace inefficient chromatographic steps with high-specificity affinity ligands to streamline downstream processing. This approach simplifies workflows and protects sensitive biomolecules.

  6. Ensure Consistency Across Batches With A Powerful Tool 5/19/2025

    Learn how to streamline bioprocess control with an innovative software's Unit Save and Load feature. Save configurations, reduce setup time, and ensure consistency across batches with this powerful tool.

  7. Dr. Peter Marks Talks a Standardized Playbook for Gene Therapy Manufacturing 1/30/2024

    In this segment, Dr. Peter Marks shares developments in CMC for advanced therapies in the near future.

  8. Advancing Vaccine Development With Novel Chromatography Solutions & Quality Testing 6/24/2025

    Learn more on novel chromatography solutions that can help improve the downstream processes of different vaccine types such as mRNA, recombinant proteins, and Virus-Like Particles (VLPs).

  9. Driving Down COGS Audience Q&A 8/18/2023

    Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.

  10. Regulatory Compliance And Viral Vectors 11/13/2023

    Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.